Aafke H. Honkoop

3.6k citations

33 papers · 1.5k indexed · h-index 17

Oncology top 2%
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 10%
Pathology and Forensic Medicine top 10%
Molecular Biology

Co-authors: Sabine C. Linn Frans Erdkamp Herbert M. Pinedo Klaas Hoekman Gabe S. Sonke Cornelis J.A. Punt Miriam Koopman Robert S. de Jong
Topics: Cancer Treatment and Pharmacology (16 papers)Breast Cancer Treatment Studies (11 papers)HER2/EGFR in Cancer Research (10 papers)
Cited by: Oncology Cancer Research Hepatology
Journals: The Lancet Journal of Clinical Oncology JNCI Journal of the National Cancer Institute
Partner nations: Netherlands United States Germany

In The Last Decade

Aafke H. Honkoop

33 papers receiving 1.5k citations

Peers

Countries citing papers authored by Aafke H. Honkoop

Since Specialization

Citations

This map shows the geographic impact of Aafke H. Honkoop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aafke H. Honkoop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aafke H. Honkoop more than expected).

Fields of papers citing papers by Aafke H. Honkoop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aafke H. Honkoop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aafke H. Honkoop. The network helps show where Aafke H. Honkoop may publish in the future.

Co-authorship network of co-authors of Aafke H. Honkoop

This figure shows the co-authorship network connecting the top 25 collaborators of Aafke H. Honkoop. A scholar is included among the top collaborators of Aafke H. Honkoop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aafke H. Honkoop. Aafke H. Honkoop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer 2023 ·JNCI Cancer Spectrum ·(unknown),Sandra M. E. Geurts,Irene E.G. van Hellemond,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Marjolein L. Smidt,Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	4
2	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial 2023 ·EClinicalMedicine ·Vivianne C. G. Tjan‐Heijnen,(unknown),Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz	11
3	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study 2021 ·Journal of Hematology & Oncology ·(unknown),Linda de Munck,Marie-Jeanne T. F. D. Vrancken Peeters,Mireille J. M. Broeders,Luc J. A. Strobbe,Monique E.M.M. Bos,Marjanka K. Schmidt,(unknown),Marjolein L. Smidt,Maud Bessems,Janneke Verloop,Sabine C. Linn,(unknown),Aafke H. Honkoop,(unknown),Pieter J. Westenend,Jelle Wesseling,C. Willemien Menke‐van der Houven van Oordt,Vivianne C. G. Tjan‐Heijnen,Sabine Siesling	67
4	Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer 2020 ·Acta Oncologica ·(unknown),Frans Erdkamp,Marta López‐Yurda,(unknown),Jeany M. Rademaker-Lakhai,Aafke H. Honkoop,Hiltje de Graaf,Vivianne C. G. Tjan‐Heijnen,Monique E.M.M. Bos	3
5	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study 2019 ·International Journal of Cancer ·Irene E.G. van Hellemond,Carolien H. Smorenburg,Petronella G.M. Peer,Astrid C P Swinkels,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	11
6	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial 2018 ·The Lancet Oncology ·Mette S. van Ramshorst,Anna van der Voort,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,Vincent O. Dezentjé,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,Agnès J. van de Wouw,Caroline M.P.W. Mandigers,Laurence J. van Warmerdam,Jelle Wesseling,Marie-Jeanne TFD Vrancken Peeters,Sabine C. Linn,Gabe S. Sonke	245
7	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure 2018 ·International Journal of Cancer ·Irene E.G. van Hellemond,Ingeborg J. H. Vriens,Petronella G.M. Peer,Astrid C P Swinkels,Carolien H. Smorenburg,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	7
8	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure 2017 ·JNCI Journal of the National Cancer Institute ·Irene E.G. van Hellemond,Ingeborg J. H. Vriens,Petronella G.M. Peer,Astrid C P Swinkels,Carolien H. Smorenburg,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Jos Kitzen,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	22
9	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. 2017 ·Journal of Clinical Oncology ·Vivianne C. G. Tjan‐Heijnen,(unknown),Ingeborg J. H. Vriens,Petronella G.M. Peer,Astrid C P Swinkels,Carolien H. Smorenburg,(unknown),Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette van den Berkmortel,Maaike de Boer,(unknown),Sabine C. Linn,Alexander L.T. Imholz,Caroline Seynaeve	1
10	A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03). 2017 ·Journal of Clinical Oncology ·Mette S. van Ramshorst,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,Vincent O. Dezentjé,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,(unknown),Caroline M.P.W. Mandigers,Jelle Wesseling,Marie‐Jeanne Vrancken Peeters,Sabine C. Linn,Gabe S. Sonke	5
11	Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer 2017 ·Pharmacological Research ·Siu W. Lam,Vincent van der Noort,Tahar van der Straaten,Aafke H. Honkoop,Godefridus J. Peters,Henk‐Jan Guchelaar,Epie Boven	15
12	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy 2016 ·Clinical Cancer Research ·Siu W. Lam,Nienke M. Nota,Agnes Jager,Monique M.E.M. Bos,(unknown),Ankie M.T. van der Velden,Johanneke E.A. Portielje,Aafke H. Honkoop,Harm van Tinteren,Epie Boven	17
13	Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors 2016 ·Journal of Cancer Survivorship ·José A. E. Custers,Marieke Gielissen,Johannes H.W. de Wilt,Aafke H. Honkoop,Tineke J. Smilde,(unknown),(unknown),Winette T.A. van der Graaf,Judith B. Prins	41
14	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial 2016 ·Cancer ·Jan C. Drooger,Harm van Tinteren,(unknown),Albert J. ten Tije,Hiltje de Graaf,Johanneke E.A. Portielje,Agnes Jager,Aafke H. Honkoop,Sabine C. Linn,Judith R. Kroep,Frans Erdkamp,Paul Hamberg,Alex L.T. Imholz,(unknown),Joan B. Heijns,A. Elise van Leeuwen‐Stok,Stefan Sleijfer	3
15	Patients’ Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist’s Awareness of These Preferences 2015 ·Journal of Cancer Education ·Linda Oostendorp,Petronella B. Ottevanger,Agnès J. van de Wouw,Aafke H. Honkoop,Maartje Los,Winette T.A. van der Graaf,Peep F. M. Stalmeier	19
16	Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial 2007 ·The Lancet ·Miriam Koopman,Ninja Antonini,(unknown),J. Wals,Aafke H. Honkoop,Frans Erdkamp,Robert S. de Jong,C. J. Rodenburg,Gerard Vreugdenhil,O. J. L. Loosveld,Aart van Bochove,Harm Sinnige,Geert-Jan Creemers,Margot Tesselaar,P. H. Th. J. Slee,(unknown),Linda Mol,Otilia Dalesio,Cornelis J.A. Punt	461
17	Management of Stage III Breast Cancer 1998 ·Oncology ·Aafke H. Honkoop,John Wagstaff,(unknown)	11
18	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	7
19	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	84
20	Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer 1997 ·American Journal of Clinical Pathology ·Aafke H. Honkoop,Herbert M. Pinedo,Johannes S. de Jong,Henk M.W. Verheul,Sabine C. Linn,Klaas Hoekman,John Wagstaff,P. J. van Diest	99

About Aafke H. Honkoop

Aafke H. Honkoop is a scholar working on Oncology, Cancer Research and Geriatrics and Gerontology, having authored 33 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (11 papers) and HER2/EGFR in Cancer Research (10 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (495 citations) and Hepatology (145 citations). Aafke H. Honkoop has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Sabine C. Linn, Frans Erdkamp, Herbert M. Pinedo, Klaas Hoekman, Gabe S. Sonke, Cornelis J.A. Punt, Miriam Koopman, Robert S. de Jong, Jelle Wesseling and Margot Tesselaar. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact